A Non-Invasive Device Improves Memory in 78% of Alzheimer's Patients

Introduction: the measured promise of a drug-free treatment

What this study actually shows

A randomized clinical study, published in the American Journal of Alzheimer's Disease and Other Dementias, reports that 78% of patients with mild cognitive impairment or early-stage Alzheimer's saw their cognition improve relative to their own baseline, after six months of treatment with a device called external counterpulsation, with no medication involved, according to data reported by Business Insider and Yahoo Finance.

This device, marketed under the name Cerezen, works by mechanically increasing blood flow to the brain, an approach completely different from the usual pharmaceutical treatments for Alzheimer's disease. Before getting carried away, though, this claim deserves the same rigor demanded by any medical topic touching the hopes of millions of families.

Why this topic deserves a real fact-check

This kind of announcement, carried by a press release from the company itself, deserves independent verification before being presented as a definitive breakthrough. That's exactly the purpose of this article: to separate what is solidly demonstrated by the clinical trial from what still amounts to commercial promotion for a product awaiting U.S. approval.

According to documents reviewed on the R Discovery platform, which lists the study published in February 2026, this is a randomized, double-blind, sham-controlled clinical trial conducted on 190 patients over twelve months — a rigorous methodology worth commending in a field where false promises have unfortunately been common in the past.

What exactly the published clinical trial says

A double-blind methodology across 190 patients

According to study data listed on R Discovery, the trial included 190 patients meeting the clinical criteria for mild cognitive impairment linked to Alzheimer's or mild Alzheimer's, based on diagnostic criteria established by the National Institute on Aging and the Alzheimer's Association. Participants were randomly assigned to a group receiving full-pressure treatment and a group receiving a sham treatment at very low pressure.

The treatment group received therapeutic pressure of 150 to 300 millimeters of mercury, compared with just 25 millimeters of mercury for the placebo group, on a schedule of three to five one-hour sessions per week for the first 35 treatments, then two sessions per week through month six. This methodical structure allows a genuine therapeutic effect to be distinguished from a simple placebo effect.

Statistically significant results on two cognitive scales

The results show an average improvement of 2.57 points on the ADCS-ADL scale, which measures daily functional independence, compared with a decline of -0.49 points in the placebo group, a statistically significant difference with a p-value of 0.036, according to the study data. On the cognitiveVADAS-cog scale, the improvement reached 9.95 points compared with 5.22 points for the placebo group, with an even stronger significance of 0.005.

A notable and scientifically reassuring detail: these benefits held through week 52 of follow-up, six months after active treatment ended, with no serious adverse events linked to the device reported throughout the entire trial.

How this external counterpulsation technology works

A mechanical principle rather than a chemical one

The Cerezen device relies on a mechanical principle already familiar in cardiology: external counterpulsation uses inflatable cuffs placed on the legs that compress in sync with the heartbeat, thereby increasing blood pressure and flow to vital organs, including the brain, according to information published by Business Insider.

This technology isn't entirely new: it's already approved in the United States for treating angina, a cardiovascular condition, which offers an additional safety argument since the device already has a recognized clinical track record in another medical context.

Targeting blood flow rather than amyloid plaques

Unlike recent pharmaceutical treatments for Alzheimer's, which generally target the removal of beta-amyloid protein plaques in the brain, this approach instead aims to correct a vascular dysfunction increasingly recognized as an important contributing factor in the disease's progression, according to explanations reported by Yahoo Finance.

This difference in approach could explain, at least in part, why this treatment appears effective where several anti-amyloid drugs have produced disappointing or modest clinical results in recent years, though it remains too early to draw definitive conclusions about the precise biological mechanisms at play.

The concrete scale of the reported cognitive improvement

Five points gained, one to two years of function restored

According to Dr. Jack Juni, chief medical advisor at Cerezen, cited by Business Insider and Yahoo Finance, participants gained on average five points on standardized cognitive scales after six months of treatment, an improvement the doctor describes as equivalent to "regaining one to two years of lost function."

This claim, though it comes from a spokesperson directly tied to the company marketing the device, is backed by data published in a peer-reviewed scientific journal, which gives it more credibility than a simple, unverified promotional statement.

Broad eligibility among Alzheimer's patients

According to the same sources, more than 70% of Alzheimer's patients could potentially be eligible for this type of treatment, a figure that, if confirmed in real-world clinical practice, would represent a therapeutic option accessible to a large majority of people affected by this neurodegenerative disease.

This broad potential eligibility contrasts with some recent pharmaceutical treatments for Alzheimer's, which often require strict inclusion criteria and costly positron emission tomography imaging scans to confirm patient eligibility for treatment.

The regulatory path, still incomplete in the United States

European certification, but not yet American approval

In the interest of journalistic honesty, it's essential to note that the Cerezen device obtained certification for treating Alzheimer's in the European Union in October 2025, under the European medical device regulation MDR 2017/745, certificate number MDR 818385, according to Business Insider and Yahoo Finance.

However, despite positive clinical results from randomized, controlled trials conducted in the United States, the device has not yet received U.S. market authorization, a crucial detail North American readers should keep in mind before getting overly excited.

A regulatory dialogue underway since 2018

The company Renew Research, behind Cerezen's development, has been in dialogue with the U.S. Food and Drug Administration since 2018, having secured several intermediate regulatory milestones over the years, including a breakthrough device designation in July 2021 and a De Novo classification review in January 2022.

These regulatory steps, encouraging as they are, in no way guarantee final FDA approval, and the path to eventual U.S. commercialization could still take several more years — an important reminder to temper the enthusiasm sparked by the published clinical trial results.

The economic argument put forward by the treatment's backers

A favorable cost-effectiveness study

A separate study conducted by the Herbert Wertheim School of Public Health and Human Longevity Science at the University of California San Diego assessed the Cerezen treatment as "cost-effective" to "highly cost-effective" for treating Alzheimer's disease, based on the incremental cost-effectiveness ratio per quality-adjusted life year, as reported by Business Insider.

This economic assessment compares favorably, according to the same sources, with several pharmaceutical treatments currently available for Alzheimer's, which earlier studies judged "not cost-effective" while offering clinical benefits the scientific community considered limited.

A considerable economic and human burden nationwide

The backdrop that makes this announcement particularly relevant is a massive health burden: more than seven million Americans aged 65 and older currently live with Alzheimer's disease, or roughly 11% of that age group, at an annual economic cost exceeding 400 billion dollars, according to data reported by Yahoo Finance.

Beyond the economic figures, millions of family caregivers face considerable emotional, physical, and financial strain caring for a loved one with this disease, a reminder that any therapeutic advance, however modest, carries a human weight far beyond raw clinical statistics.

What this fact-check confirms and what it cannot guarantee

What is solidly established by the available data

Based on the sources reviewed, it's possible to state with a reasonable degree of confidence that the randomized, controlled clinical trial did indeed show a statistically significant improvement on two recognized cognitive scales, among patients with mild cognitive impairment or early-stage Alzheimer's, after six months of external counterpulsation treatment, with no serious adverse events reported.

These results were also subjected to review by a peer-reviewed scientific journal, the American Journal of Alzheimer's Disease and Other Dementias, which provides a minimal guarantee of methodological rigor far exceeding that of a simple, unverified commercial announcement.

What remains uncertain and still needs to be proven

What remains uncertain, however, is the long-term durability of the benefits beyond one year of follow-up, the real scale of the 70% eligibility figure put forward by the company, as well as the timeline and final outcome of the approval process with the U.S. FDA, which remains uncertain to this day despite years of regulatory dialogue dating back to 2018.

This fact-check therefore concludes that the central claim of 78% cognitive improvement after six months of treatment is corroborated by published, verifiable clinical trial data, while noting that this technology remains, for now, legally unavailable in North America and that its widespread clinical adoption remains hypothetical.

How this treatment compares with currently available options

Existing drugs with often limited benefits

Recently approved pharmaceutical treatments for Alzheimer's disease, particularly those targeting the removal of amyloid plaques, have often produced clinical benefits the scientific community considers modest, while requiring regular infusions, close medical monitoring, and costly imaging scans to confirm patient eligibility.

By comparison, the Cerezen device offers the theoretical advantage of avoiding these heavy burdens, without infusions or positron emission tomography scans, a practical difference that could make treatment more accessible to a larger number of patients if its U.S. approval eventually succeeds.

Possible complementarity rather than total replacement

Based on currently available data, it would be premature to claim that this mechanical approach will entirely replace existing pharmaceutical treatments for Alzheimer's. It's more likely, if the results hold up at larger scale, that this type of device becomes a complement to current drug-based approaches rather than a sole substitute.

This potential complementarity between mechanical and pharmaceutical approaches reflects a broader trend in contemporary medical research against neurodegenerative diseases, which increasingly recognizes the multifactorial nature of these conditions rather than searching for a single, miraculous solution.

Conclusion: a real advance, but still to be confirmed at scale

An encouraging signal in a field marked by disappointment

This study on external counterpulsation represents an encouraging signal in a medical research field that has seen, over recent decades, more clinical failures than resounding successes against Alzheimer's disease. The trial's methodological rigor, with its placebo group and randomization, deserves recognition as a clear positive.

Patience and vigilance remain essential for affected families

For North American families hoping for quick access to this treatment, patience nonetheless remains necessary: between the still-uncertain U.S. approval process and the need for longer-term follow-up data, this treatment doesn't yet represent an accessible option today, but rather a serious lead worth watching closely in the months and years ahead.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I am neither a doctor nor a neurology researcher; I rely on published clinical trial data and verified journalistic and financial reporting to write this fact-check. My approach consistently favors measured hope over medical sensationalism, an editorial stance I fully own when covering topics as sensitive as Alzheimer's disease.

What I don't know

I cannot guarantee the durability of cognitive benefits beyond the studied follow-up period, nor predict the timeline or outcome of this device's U.S. approval process, matters that lie well beyond the scope of my expertise as a generalist columnist and require ongoing scientific and regulatory tracking that I commit to following in future articles.

Sources

Primary sources

R Discovery — Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation, A Randomized Clinical Trial, published February 2026

American Journal of Alzheimer's Disease and Other Dementias — official journal website

Secondary sources

Business Insider — Trial Validates First Treatment to Actually Improve Alzheimer's Disease, July 2, 2026

Yahoo Finance — Trial Validates First Treatment to Actually Improve Alzheimer's Disease, July 2, 2026

Azat TV — Alzheimer's Disease Clinical Advancements and Stigma, 2026

Alzheimer's Association — official resources on Alzheimer's disease and NIA-AA diagnostic criteria, 2026